Ardelyx Gets IBS-C Approval, But Focus Remains On Hyperphosphatemia

 
• By Joseph Haas

Tenapanor approved for IBS-C as Ibsrela, but Ardelyx is still seeking a commercial partner for that indication – and is maintaining focus on same molecule in hyperphosphatemia.

FDA Approved text on medical doctor blur lights background. - Image
Ardelyx got its first drug approval, but has no plans to launch Ibsrela on its own • Source: Shutterstock

More from New Products

More from Scrip